Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2091-2099

  MacKeigan, Jeffrey P ^a   Taxman, Debra J ^a   Hunter, Deborah ^a   Earp III, H Shelton ^a   Graves, Lee M ^a   Ting, Jenny P Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; APOPTOSIS INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; MORPHOLINE DERIVATIVE; NEU DIFFERENTIATION FACTOR; NITRILE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL CULTURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; IMMUNOBLOTTING; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; PHOSPHORYLATION; PLASMID;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, NORTHERN; BUTADIENES; CHROMONES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMAN; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; NEUREGULIN-1; NITRILES; PACLITAXEL; PHOSPHORYLATION; PLASMIDS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 0035992286     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Promotion of microtubule assembly in vitro by Taxol
2. Taxol stabilizes microtubules in mouse fibroblast cells
3. Taxol binds to polymerized tubulin in vitro
4. Shared actions of endotoxin and Taxol on TNF receptors and TNF release
5. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages
6. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity
7. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages
8. Lipopolysaccharide antagonists block Taxol-induced signaling in murine macrophages
9. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter
10. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
11. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
12. Mechanisms of Taxol-induced cell death are concentration dependent
13. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts
14. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways
15. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK)
16. Constitutive nuclear NF κB/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate
17. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
18. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
19. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
20. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
21. Ting MEK inhibition enhances paclitaxel-induced tumor apoptosis
22. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines
23. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway
24. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
25. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B
26. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
27. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
28. Regulation of cell death protease caspase-9 by phosphorylation
29. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
30. Phosphorylation and regulation of Raf by Akt (protein kinase B)
31. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
32. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis
33. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors
34. Identification of class II transcriptional activator-induced genes by representational difference analysis: Discoordinate regulation of the DN α/DO β heterodimer
35. Untangling the ErbB signalling network
36. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region
37. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain
38. Protein kinase B and rac are activated in parallel within a phosphatidylinositide 3OH-kinase-controlled signaling pathway
39. Regulation of neuronal survival by the serine-threonine protein kinase Akt
40. A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma
41. Second-line chemotherapy for recurrent non-small cell lung cancer: Do new agents make a difference?
42. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways
43. Modulation of cellular apoptotic potential: Contributions to oncogenesis
44. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
45. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
46. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
47. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
48. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
49. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia